NUTX

ANALYST NOTE: NUTX (Nutex Health, Inc.) Date: 2026-06-13 Current Price: $150.51

1. Structural Readiness

• State: Context-Only.
• Conservative Entry: — (Pending breakout confirmation).
• Aggressive/Pre-Breakout Entry: — (Not recommended for conservative sizing; requires specific risk parameters not defined in the current setup state).
• Breakout Level: — (Pending).
• Current Price: $150.51.
• Extension: — (No extension data provided relative to the breakout level).
• ATR Context: Current ATR is 5.2% (High). This indicates elevated volatility, which is within the historical "sweet spot" (4–6%) for structural setups, suggesting sufficient liquidity and movement potential, though requiring careful position sizing.

2. Thesis Layer

• Thesis Classification: Tactical / Setup-Led.
• Analysis: As of 2026-06-13, there is no named secular thesis attached to Nutex Health in the provided evidence base. The investment case is not driven by a macro secular trend (e.g., "aging population" or "AI in healthcare") explicitly named in the source data.
• Judgment Criteria: The conviction must be derived strictly from the quality of the technical setup (the forming coil) and the fundamental business execution (expansion and operational metrics) recorded by management. Do not invent a macro narrative; judge the name on its ability to execute its stated growth plan and the structural integrity of its price action.

3. Business Overview

Nutex Health, Inc. operates as a physician-led healthcare services and operations company structured into two primary segments:

• Hospital Division: Develops and operates a network of micro-hospitals, specialty hospitals, and Hospital Outpatient Departments (HOPDs).
• *Scale:* As of March 31, 2026, the company owned and operated 27 hospital facilities across 12 states (E8).
• *Growth:* Management expects to open 3 additional hospitals in Q3 and Q4 2026 (San Antonio, Jacksonville, West Little Rock) (E1).
• *Cost Structure:* Each new project is estimated to cost between $20 million and $30 million (E3).
• *Revenue:* Q1 2026 total revenue reached $216.5 million, a 2% increase year-over-year (E4).
• *Utilization:* Hospital patient visits reached 49,700 in Q1 2026, up 3.1% from the prior year (E5).
• Population Health Management (PHM) Division: A risk-bearing, primary care-centric division managing provider networks (IPAs).
• *Scale:* Oversees approximately 40,000 patients across Medicare Advantage, commercial, and Medicaid managed care (E6).
• *Network:* Manages one IPA in Los Angeles with over 230 PCPs and 2,800 specialists (E19).
• *Growth:* Management anticipates launching one to three additional IPAs per year (E23).

Operational Model:

• Revenue Source: Greater than 99% of net patient service revenue is paid by insurers, federal agencies, and third parties (E10).
• Workforce: Employs approximately 1,005 full-time employees and contracts with over 280 doctors at facilities, partnering with over 3,600 physicians in networks (E9).
• Technology: Utilizes a proprietary, cloud-based platform to aggregate patient/provider data for holistic care delivery (E28).

4. Archetype and Conviction Stack

• Archetype Candidate: Growth Leader / Expansion Operator.
• *Fit:* The company is in a clear expansion phase, moving from 26 facilities (Dec 2025) to 27 (Mar 2026) with a pipeline of 3-4 new openings in 2026 and 4-5 in 2027 (E1, E2, E17, E18). The business model relies on scaling a high-margin, asset-light management model (micro-hospitals) supported by a growing PHM network.
• Valuation Context:
• Forward consensus EPS for FY1 is $21.22 and FY2 is $22.75 (E29).
• At a current price of $150.51, the stock trades at approximately 7.1x FY1 forward EPS and 6.6x FY2 forward EPS. This suggests a valuation that prices in significant growth but leaves room for multiple expansion if execution remains on track.
• Conviction Stack:
• *Thesis Strength:* Low (No named secular thesis; purely tactical).
• *Evidence Quality:* High (Strong, specific management guidance on facility openings, costs, and revenue growth; clear financial spine).
• *Setup Readiness:* Partial (Forming coil requires breakout confirmation).
• *Rerating Potential:* Moderate (Dependent on successful execution of the 2026/2027 expansion and the resolution of the IDR/No Surprises Act environment).

5. Invalidations, Strengths, and Gaps

• What Would Strengthen the Case:
• Execution of Guidance: Successful opening of the 3 planned hospitals in Q3/Q4 2026 without cost overruns (E1).
• IDR Success: Continued high success rates in Independent Dispute Resolution (IDR) proceedings, where providers prevailed in 88% of determinations in the first half of 2025 (E13).
• What Would Invalidate the Case:
• Regulatory Headwinds: Passage of the "No Surprises Enforcement Act" (introduced July 2025) imposing financial penalties on insurers for late payments, which could disrupt cash flow or increase arbitration costs (E15).
• Cost Escalation: If the cost to build new facilities exceeds the $20M-$30M estimate significantly, or if the 4-5 projects planned for 2027 face financing delays (E2).
• Gaps in Evidence:
• Profitability Margins: While revenue and patient visits are cited, specific net income or operating margin figures for Q1 2026 are not explicitly detailed in the provided evidence, only revenue growth.
• Cash Position: No specific cash balance or liquidity runway data is provided for the current date.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Management guidance to open 3 hospitals in H2 2026 and 4-5 in 2027; Forward EPS of $21.22 implies significant growth; 88% provider win rate in IDR disputes supports revenue quality. Key risks: Technical setup is forming, not confirmed; Regulatory uncertainty regarding the No Surprises Enforcement Act; High ATR (5.2%) indicates elevated volatility risk. Sizing hint: Position size should be reduced relative to a confirmed breakout setup due to the "forming" status and lack of a named secular thesis. Expected horizon: 3 to 6 months for setup confirmation or invalidation.